OpenEvidence Medical AI Valued at $15 Billion as It Expands
Understand the story
According to a Financial Times report (as cited by Ars Technica), medical AI startup OpenEvidence is currently valued at $15 billion, with advertising as its main revenue model. Company founder Nadler said the company's end goal is to pursue literature-based drug discovery, adding that the economic value of this direction will far exceed the current model of charging hospitals or advertisers.
AI overview of reporting · Updated 3 h前
Reporting timeline
Explore different aspects of the story through its reporting.
- Ars Technica · AIThe $15 billion ad-powered AI startup your doctor may already be using
The Financial Times profiles OpenEvidence, a medical AI company valued at $15 billion that makes money through advertising. Founder Nadler says the end goal is literature-based drug discovery, which he believes will create economic value far beyond charging hospitals or advertisers.
Story heat trend
Current heat9·Comparable peak10（10/22 00:00）·Comparable change over 24 hours –
The trend compares the same continuously observed sources, which may cover fewer sources than the current heat score. Hover or select the chart to inspect each hour; use the left and right arrow keys to navigate.